TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04248920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic to Community Education Program
Description: The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinic to Community Education Program
Description: The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
Study: NCT04942015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honghuaruyi Wan
Description: Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Honghuaruyi Wan
Description: Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
Study: NCT05401812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Description: Betamethasone, dexamethasone, or methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Description: Betamethasone, dexamethasone, or methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Description: Betamethasone, dexamethasone, or methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Description: Betamethasone, dexamethasone, or methylprednisolone
Study: NCT05545995

Intervention type: OTHER
Intervention: embryo selection
Description: The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A

Intervention type: OTHER
Intervention: embryo selection
Description: The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
Study: NCT05911724

Intervention type: OTHER
Intervention: Group I Healthy
Description: Healthy Subjects

Intervention type: DRUG
Intervention: CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Description: Group II: Stable Angina Patients

Intervention type: DRUG
Intervention: HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Description: Group III: Heart Failure Patients
Study: NCT05527184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN151
Description: IMGN151 is an antibody-drug conjugate (ADC).
Study: NCT05088083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
Description: After predilation, using drug-coated balloon catheter to cover the whole treated segment
Study: NCT05449379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory training with the use of resistance set on respiratory muscle trainer
Description: Performing respiratory training with resistance set on respiratory trainer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory training without resistance set on respiratory muscle trainer
Description: Performing respiratory training with no resistance set on respiratory trainer
Study: NCT04407650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre
Study: NCT06223256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBL-028
Description: Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
Study: NCT05704543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Extended-Release Injection
Description: Administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Extended-Release Injection
Description: Administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Extended-Release Injection
Description: Administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Extended-Release Injection
Description: Administered as a subcutaneous injection.
Study: NCT06520657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Participants are screened for social determinants of health and work with a community health worker for three months to connect them with community and government services to address their family's needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child weight management intervention
Description: This is a 12-week family-based behavioral group intervention to address childhood overweight and obesity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child weight management intervention
Description: This is a 12-week family-based behavioral group intervention to address childhood overweight and obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care referral to resources
Description: One-time referral to resources based on need that families can access independently either by providing electronic referral to or providing written contact information for a community resource.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care referral to resources
Description: One-time referral to resources based on need that families can access independently either by providing electronic referral to or providing written contact information for a community resource.
Study: NCT06264219

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome restoration - FMT
Description: Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome restoration - FVT
Description: Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive solution buffer

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal birth, untreated control
Description: No intervention. This group is for secondary outcomes comparisons.
Study: NCT05427734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WisePath for Adults
Description: Participants assigned to this condition will receive access to the WisePath app for 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-Control app + electronic wellness resources brochure
Description: Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
Study: NCT05627531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Medicine
Description: Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
Study: NCT05977621

Intervention type: OTHER
Intervention: Transrectal ultrasound (TRUS)
Description: Transrectal ultrasound (TRUS) images of the female pelvis

Intervention type: OTHER
Intervention: Transrectal ultrasound (TRUS)
Description: Transrectal ultrasound (TRUS) images of the female pelvis
Study: NCT05643183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astmakompas
Description: The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
Study: NCT06489821

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
Study: NCT06289608

Intervention type: OTHER
Intervention: No intervention
Description: No dental intervention was made. Only a clinical examination
Study: NCT04889469

Intervention type: PROCEDURE
Intervention: Breast reduction
Description: Procedure to remove excess fat, tissue and skin from the breasts.
Study: NCT05725811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic foam rolling
Description: The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic foam rolling
Description: The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
Study: NCT03757897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
Study: NCT04748341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)
Description: The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Method
Description: The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins
Study: NCT06069245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: 80mg of MitoQ taken in one dose on one occasion.
Study: NCT04813133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized Lifestyle Modification Program
Description: Synchronization of dietary intake with circadian rhythm of the body.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized Lifestyle Modification Program and Physiotherapy
Description: Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
Study: NCT06069245

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules
Study: NCT05611879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)
Description: Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
Study: NCT06474364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting Cabotegravir injection
Description: Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting Cabotegravir injection
Description: Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.

Intervention type: OTHER
Group type: OTHER
Intervention: SEARCH-YOUTH
Description: It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.
Study: NCT06141590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UI068
Description: Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UIC202205, UIC202206
Description: Reference
Study: NCT06479798

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)
Description: Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
Study: NCT04931862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Artificial cerebrospinal fluid (aCSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Artificial cerebrospinal fluid (aCSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Artificial cerebrospinal fluid (aCSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Artificial cerebrospinal fluid (aCSF)
Study: NCT06142045

Intervention type: DEVICE
Intervention: RespirACT RA-MR System
Description: RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.

Intervention type: DEVICE
Intervention: RespirACT RA-MR System
Description: RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.

Intervention type: DEVICE
Intervention: RespirACT RA-MR System
Description: RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
Study: NCT04813133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
Study: NCT05586061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin
Description: Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
Study: NCT04529070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nightmare Rescripting and Rehearsal
Description: This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard of care
Description: standard of care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard of care
Study: NCT06560164

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell transfusion
Description: When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell transfusion
Description: When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.
Study: NCT06560138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: SHR-4602 will be administered through IV infusion.
Study: NCT05899595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise protocol
Description: Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises.
Study: NCT05763576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7565020
Description: RO7565020 will be administered by subcutaneous injection or intravenous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered by subcutaneous injection or intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NUC) treatment
Description: NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
Study: NCT05867836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA vs. MMS during pregnancy
Description: Iron and folic acid, or multiple micronutrient supplements provided during pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA vs. MMS during pregnancy
Description: Iron and folic acid, or multiple micronutrient supplements provided during pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA vs. MMS during pregnancy
Description: Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
Study: NCT06345794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Administered orally.
Study: NCT06582043

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily